<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5271">
  <stage>Registered</stage>
  <submitdate>19/04/2015</submitdate>
  <approvaldate>19/04/2015</approvaldate>
  <nctid>NCT02424136</nctid>
  <trial_identification>
    <studytitle>PEAnut Anaphylaxis Predictors</studytitle>
    <scientifictitle>PEAnut Anaphylaxis Predictors</scientifictitle>
    <utrn />
    <trialacronym>PEAAP</trialacronym>
    <secondaryid>PEAAP (14/12/12/4.12)</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Peanut Hypersensitivity</healthcondition>
    <healthcondition>Anaphylaxis</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Allergies</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Questionnaire
Other interventions - Peanut Skin prick test
Other interventions - Fraction of exhaled nitric oxide
Other interventions - Spirometry
Other interventions - Serum Peanut and Ara h2 specific immunoglobulin E
Other interventions - Collection of blood biomarker
Other interventions - Peanut food challenge

Other: Entire group - Children aged 6-17 years with suspected peanut allergy who require peanut food challenge to confirm clinical allergy, will be recruited for the study. They will undergo a preceding questionnaire, peanut skin prick testing, spirometry, fraction of exhaled nitric oxide (FeNO) measurement, serum peanut and Ara h2 specific immunoglobulin E (sIgE) antibodies, and collection of blood biomarker prior to food challenge. The primary endpoint will be anaphylaxis at open label peanut challenge, with the primary exposure of interest will be the serum biomarker.


Other interventions: Questionnaire
5 minute questionnaire focused on symptoms of allergic disease

Other interventions: Peanut Skin prick test
Skin prick testing with peanut antigen, according to ASCIA Skin Prick testing manual

Other interventions: Fraction of exhaled nitric oxide
Measurement of exhaled nitric oxide, according to American Thoracic Society/ European Thoracic Society (ATS/ERS) standardised procedures

Other interventions: Spirometry
Measurement of lung flows/volumes, according to ATS/ERS standardised procedures

Other interventions: Serum Peanut and Ara h2 specific immunoglobulin E
Peanut and Ara h2 specific IgE antibodies

Other interventions: Collection of blood biomarker
Correlation of blood biomarker levels in patients with successful or unsuccessful peanut food challenge

Other interventions: Peanut food challenge
Open label peanut challenge conducted according to ASCIA's peanut challenge protocol and PRACTALL consensus report

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Blood biomarker predicting anaphylaxis at peanut food challenge - The primary outcome of the project is to confirm that a novel blood biomarker has a higher diagnostic accuracy as compared to current best testing in predicting anaphylaxis at open label peanut challenge.</outcome>
      <timepoint>At completion of peanut food challenge</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Blood biomarker in combination with FeNO, and/or Ara h2 sIgE predicting anaphylaxis at peanut food challenge - The secondary outcome will be to determine the value of the biomarker, FeNO and Ara h2 sIgE (individually and in combination) at predicting anaphylaxis or clinical allergy at open label peanut challenge.</outcome>
      <timepoint>At completion of peanut food challenge</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Children aged 6 - 17 years with an allergy to peanut and require peanut challenge to
             confirm peanut allergy.</inclusivecriteria>
    <inclusiveminage>6</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>17</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Children with Peanut Skin Prick Test (SPT) wheal size greater than 10mm as these
             children are likely to have clinical peanut allergy (no clinical indication for food
             challenge).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>400</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>John Hunter Children's Hospital - New Lambton</hospital>
    <postcode>2305 - New Lambton</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>John Hunter Children's Hospital</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Hunter Medical Research Institute, Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>University of Newcastle, Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Thrasher Research Fund</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Hunter Childrens Research Foundation, Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Aerocrine AB</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Peanut allergy can be life-threatening. Current diagnostic techniques for peanut allergy have
      high sensitivity, but not high specificity. This clinical trial will test the validity of a
      novel blood biomarker (compared with current testing) as a diagnostic predictor of
      anaphylaxis to peanut.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02424136</trialwebsite>
    <publication>Sampson HA, Gerth van Wijk R, Bindslev-Jensen C, Sicherer S, Teuber SS, Burks AW, Dubois AE, Beyer K, Eigenmann PA, Spergel JM, Werfel T, Chinchilli VM. Standardizing double-blind, placebo-controlled oral food challenges: American Academy of Allergy, Asthma &amp; Immunology-European Academy of Allergy and Clinical Immunology PRACTALL consensus report. J Allergy Clin Immunol. 2012 Dec;130(6):1260-74. doi: 10.1016/j.jaci.2012.10.017.
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005 Aug;26(2):319-38.
American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005 Apr 15;171(8):912-30.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Joerg Mattes, MD</name>
      <address>John Hunter Children's Hospital, Australia</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Joerg Mattes, MD</name>
      <address />
      <phone>+61 2 49855277</phone>
      <fax />
      <email>joerg.mattes@hnehealth.nsw.gov.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>